Table 3.
Results of the multiple regression analysis
| Variable | B ± SEM | P |
|---|---|---|
| Dapagliflozin (vs. comparators) | −26.42 ± 13.14 | 0.045 |
| Age, y | 0.39 ± 0.57 | 0.497 |
| BMI, kg/m2 | 0.49 ± 0.86 | 0.564 |
| Diastolic blood pressure, mm Hg | −0.36 ± 0.47 | 0.444 |
| Fasting plasma glucose, mg/dL | −0.45 ± 0.18 | <0.001 |
| HbA1c, % | −4.14 ± 5.02 | 0.410 |
| Triglycerides, mg/dL | 0.02 ± 0.04 | 0.585 |
| SGPT, U/L | 0.12 ± 0.24 | 0.618 |
| eGFR, mL/min/1.73 m2 | 0.33 ± 0.29 | 0.251 |
| Insulin use (yes vs. no) | −2.80 ± 11.4 | 0.806 |
| Metformin use (yes vs. no) | 24.50 ± 13.27 | 0.065 |
| Diuretic use (yes vs. no) | −7.19 ± 11.16 | 0.520 |
| Microangiopathy (yes vs. no) | −17.61 ± 8.80 | 0.045 |
Change in AER was the dependent variable, whereas covariates were selected as variables that remained different between the two groups after Bonferroni correction (see Table 1).